- Home
- BY vs MLYS Comparison
BY vs MLYS Comparison
Compare BY & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BY
- MLYS
- Stock Information
- Founded
- BY 1914
- MLYS 2019
- Country
- BY United States
- MLYS United States
- Employees
- BY N/A
- MLYS N/A
- Industry
- BY Major Banks
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- BY Finance
- MLYS Health Care
- Exchange
- BY Nasdaq
- MLYS Nasdaq
- Market Cap
- BY 1.1B
- MLYS 1.0B
- IPO Year
- BY 2017
- MLYS 2023
- Fundamental
- Price
- BY $25.81
- MLYS $15.56
- Analyst Decision
- BY Hold
- MLYS Strong Buy
- Analyst Count
- BY 3
- MLYS 3
- Target Price
- BY $33.67
- MLYS $33.00
- AVG Volume (30 Days)
- BY 133.8K
- MLYS 866.7K
- Earning Date
- BY 07-24-2025
- MLYS 05-12-2025
- Dividend Yield
- BY 1.55%
- MLYS N/A
- EPS Growth
- BY N/A
- MLYS N/A
- EPS
- BY 2.69
- MLYS N/A
- Revenue
- BY $379,386,000.00
- MLYS N/A
- Revenue This Year
- BY $16.23
- MLYS N/A
- Revenue Next Year
- BY $3.79
- MLYS N/A
- P/E Ratio
- BY $9.62
- MLYS N/A
- Revenue Growth
- BY 3.48
- MLYS N/A
- 52 Week Low
- BY $21.96
- MLYS $8.24
- 52 Week High
- BY $32.89
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- BY 43.73
- MLYS 55.06
- Support Level
- BY $25.57
- MLYS $14.75
- Resistance Level
- BY $27.30
- MLYS $16.11
- Average True Range (ATR)
- BY 0.35
- MLYS 0.90
- MACD
- BY -0.15
- MLYS -0.07
- Stochastic Oscillator
- BY 7.51
- MLYS 46.03
About BY Byline Bancorp Inc.
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.